Programme(s) to which this project applies:
|☑ MPhil/PhD||☒ MRes[Med]||☒ URIS|
The ultimate goal of this project is to develop an inhaled drug powder formulation via cocrystal engineering and nanotechnology for COVID-19. Specifically, we plan to:
Students with prior knowledge and experience in pulmonary drug delivery, cocrystal engineering and/or nanoparticles fabrication are strongly encouraged to join this interesting project.
Dr ASF Chow, Department of Pharmacology and Pharmacy
Dr Aviva SF Chow currently is an Assistant Professor in the Department of Pharmacology and Pharmacy at the University of Hong Kong (HKU). With a mixed training in chemical engineering and pharmaceutical sciences, Dr Chow’s research expertise is in advanced drug delivery using cocrystal engineering and nanotechnology. He has published a number of research papers in leading journals (e.g., Acta Pharmaceutica Sinica B, European Journal of Pharmaceutics and Biopharmaceutics, International Journal of Pharmaceutics, Molecular Pharmaceutics) regarding fabrication of drug cocrystals and nanoparticles. Prior to joining the HKU, he worked as a Technical Lead and Research Scientist at Jacobson Pharma Corporation Limited for drug development and product reformulation.
For more information or to express interest for this project, please email the supervisor or the specified contact point in the project description. Interested candidates are advised to enclose with your email:
Information on the research programme, funding support and admission documentations could be referenced online at the Research Postgraduate Admissions website.
General admission enquiries should be directed to firstname.lastname@example.org.